TD Cowen maintains Caris Life Sciences at Buy, raises price target to $38 from $36

TD Cowen kept its Buy rating on Caris Life Sciences and increased its price target to $38 from $36, suggesting a 14.4% upside from the Nov 4 close of $33.22. Recent analyst price targets for the company range from $30 to $38.

Original reporting
Published Nov 5, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TD Cowen maintains Caris Life Sciences at Buy, raises price target to $38 from $36 — source image
Decision brief

The 30-second read

Med
01

Why it matters

Analyst price‑target lift signals confidence in upcoming data, but market reaction may be modest.

02

Market read

The new target may attract short‑term buying, but overall impact is limited.

03

What to watch

Potential regulatory or trial setbacks not reflected in the new target.

Relevance 6/10Novelty 5/10Timing: intraday today

Background

Caris Life Sciences is a clinical‑stage biotech focused on cancer diagnostics.

Market effects

May boost sentiment in the biotech/life‑sciences sector as peers are re‑rated.

Limited to US markets where CRIS trades.

Minimal global impact beyond niche investors.

Counterpoint

The target raise could be premature if upcoming trial data disappoints.

Key entities

  • TD Cowen

    Equity research firm that issued the rating and target.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.